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BACKGROUND: Relapse risk assessment and individual treatment recommendations remain suboptimal for breast cancer patients. In the
light of existing preclinical and clinical data, we studied NT5E (50-nucleotidase, ecto) expression and NT5E CpG island methylation in
breast cancer.
METHODS: We used RT–PCR, qPCR, methylation-specific PCR and pyrosequencing to analyse NT5E in breast carcinoma cell lines and
primary and breast carcinomas.
RESULTS: NT5E CpG island methylation was inversely associated with NT5E expression in breast carcinoma cell lines. In clinical series,
patients whose primary tumours had NT5E CpG island methylation were less likely to develop metastasis (P¼ 0.003, OR¼ 0.34, 95%
CI: 0.17–0.69). In 3/4 paired samples, NT5E was methylated in primary tumours and demethylated in CNS metastases. Patients
progressing to non-visceral as compared with visceral metastases were more likely to have NT5E CpG island methylation in primary
tumours (P¼ 0.01, OR¼ 11.8). Patients with tumours lacking detectable methylation had shorter disease-free survival (DFS)
(P¼ 0.001, HR¼ 2.7) and overall survival (OS) (P¼ 0.001, HR¼ 3). The favourable prognostic value of NT5E methylation was
confirmed in oestrogen receptor negative (P¼ 0.011, HR¼ 3.27, 95% CI: 1.31–8.12) and in triple negative cases (P¼ 0.004;
HR¼ 6.2, 95% CI: 1.9–20). Moreover, we observed a more favourable outcome to adjuvant chemotherapy in patients whose
tumours were positive for NT5E CpG island methylation: DFS (P¼ 0.0016, HR¼ 5.1, 95% CI: 1.8–14.37) and OS (P¼ 0.0005,
HR¼ 7.4, 95% CI: 2.416–23.08).
CONCLUSION: NT5E CpG island methylation is a promising breast cancer biomarker.
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Prognostic and predictive factors used to inform optimal treatment
approaches for individual breast cancer patients have gradually
moved over the last three decades from clinico-pathological
features defined by mathematical probabilistic approaches towards
biological and eventually genetic biomarkers (Perou et al, 2000;
Paik et al, 2004; Andreopoulou and Hortobagyi, 2008). Current
state-of-the-art approaches that take into consideration oestrogen
receptor (ER), progesterone receptor and HER-2 expression in
primary tumours advanced, albeit modestly, personalised breast
cancer therapy. However, numerous patients continue to derive
little benefit from their treatment (Korde and Gralow, 2011;
Perez, 2011). Recently, the introduction of microarray-based gene
expression refreshed the prospects for more accurate personalised
approaches (Sotiriou et al, 2003; Roukos et al, 2007). However,
relapse risk profiling and thereof treatment recommendations still
remain suboptimal. Existing microarray-based gene-expression
profiling tests are only slow progressing in overtaking classical
markers as more accurate prognostic systems and predictors
of response to specific therapeutics and are not yet established in
clinical practice (Sotiriou and Pusztai, 2009).
Translational cancer research has recently started focusing on
epigenetics as a novel and rich source of potential biomarkers
(Visvanathan et al, 2006). In this context, methylation markers
appear particularly promising for being cost-effective, biologically
plausible and technically straightforward, which conform to
suggested principles for breast cancer biomarker evaluation
(McGuire, 1991).
NT5E (5’-nucleotidase, ecto) is located at 6q14-q21 (NC_0000
06.11) and encodes CD73, a plasma membrane protein that
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catalyses the conversion of extracellular nucleotides to membrane-
permeable nucleosides (Boyle et al, 1988). CD73 belongs to the
50-nucleotidase family that have diverse physiological roles,
especially in controlling nucleotide kinetics (Zimmermann,
1992). Evidence from a number of experimental systems suggests
that expression of NT5E/CD73 may be important in increasing the
invasive and metastatic properties of cancers and studies have
shown that overexpression of NT5E may contribute to progression
of breast cancer via generation of adenosine nucleoside (Zhou
et al, 2007a; Zhou et al, 2007b). In breast cancer cell lines, NT5E
overexpression results in an aggressive breast cancer phenotype
and ectopic expression of NT5E in MCF-7 cells promotes cell
viability, cell cycle progression and tumourigenesis (Wang et al,
2008). Conversely, depletion of NT5E mediated by inhibitory RNA
causes reduction in cell growth rate, G0/G1 arrest and increased
apoptosis in the triple-negative MDA MB 231 breast carcinoma cell
line (Zhi et al, 2010). Moreover, animal models of cancer support a
critical function for NT5E in mediating metastasis and hindering
antitumour immunity (Stagg et al, 2011).
Given the proposed involvement of NT5E in malignant
progression and apoptosis (Ujhazy et al, 1996; Mikhailov
et al, 2008) there have been few translational studies of NT5E in
breast cancer (Kruger et al, 1991; Spychala et al, 2004). In the latter
study it was suggested that NT5E is suppressed by ERa, but little
else is known about the mechanisms regulating expression of
NT5E either in breast cancer or more generally in neoplasia.
Methylation-dependent transcriptional silencing is a key
genome regulatory mechanism, crucial for organism development
and cellular differentiation, by which gene promoters are repressed
impeding the transcription of dependent genes and thereof the
production of encoded proteins (Jaenisch and Bird, 2003).
Characteristic gene promoter methylation/demethylation occurs
in cancer, which can involve either cancer-promoting or tumour-
suppressing genes, and may serve as novel cancer biomarkers
(Lopez et al, 2009). Here, we assessed the DNA methylation status
of the NT5E CpG island in breast cancer and investigated for
clinical relevance.
MATERIALS AND METHODS
Cell lines
Fourteen breast carcinoma cell lines (MDA MB 231, MDA MB 361,
MDA MB 436, MDA MB 453, MDA MB 468, MCF-7, GI101, T47D,
MCF12A, ZR75.1, MB 157, NCI, BT20 and CAL51) and a human
mammary epithelial cell line were grown as described previously
(Shah et al, 2009). Genomic DNA was extracted from cell pellets
using the DNeasy Mini kit (Qiagen, Crawley, UK) according to the
manufacturer’s instructions. Total RNA was extracted using Trizol
(Invitrogen, Paisley, UK). cDNA was synthesised from 1 mg total
RNA using oligo (dT) primers and the ImProm-II reverse
transcriptase kit (Promega, Southampton, UK). For demethylation,
cells were treated with 5 mM 50 azacytidine (50 AZA; Sigma, St Louis,
MO, USA) for 7 days. The cells were split every 2–3 days with the
addition of fresh drug. After drug treatment, cells were harvested
for qPCR.
Clinical material
The study was performed with local ethical committee approval.
NT5E was analysed in three independent breast cancer clinical series.
 Eighty-three predominantly ER-positive primary breast carci-
nomas from northern Italy.
 Twenty-three surgically resected, histologically confirmed CNS
metastases from patients with breast carcinomas. In four patients,
paired primary cancers were available and also analysed.
 One hundred and fifty-seven primary breast carcinomas from
Tayside, Scotland; of which, 119 were ER positive, 11 were
HER-2 positive only and 26 were triple negative breast cancer
(TNBC).
In series I and III, cancers were randomly selected from the
tissue archives and only included in the study following
confirmation by an expert, specialist breast pathologist of
(i) original diagnosis (ii) sufficient neoplastic cell representation.
Cases from series II (CNS metastases) were identified by searching
the neuropathology archives for cases of resected space occupying
lesions. Cases were confirmed by histopathology to be metastatic
breast carcinomas and tumour cell representation was again
verified by histopathology. In series I and series III, we
investigated the effect of NT5E CpG island methylation on risk
of future relapse with metastatic disease and (for series III) the
effect on clinical outcome. In series II, we analysed the frequency
of NT5E CpG island methylation in metastatic breast carcinomas
and for a subset of the cases, we compared methylation in primary
and metastatic lesions. In all cases, expression of ER, PgR and
HER-2 was determined according to normal protocols of clinical
care. Staging and clinical follow-up were done according to
standard clinical guidelines in each institution, typically with 3
monthly follow-up post-surgery and imaging (mammography and
CT scans) where indicated, according to local guidelines. In series I
and III, patients were treated adjuvantly according to normal
clinical protocols. ER-positive patients were treated adjuvantly
with endocrine therapy according to clinical guidelines at the time
of treatment. This was typically with tamoxifen for 5 years.
Isolation of genomic DNA was using Proteinase K for the formalin-
fixed, paraffin-embedded cases (series I and II) and as described
previously for series III (Shah et al, 2009).
For statistical purposes, patients were grouped to those with
non-visceral metastases, identified by bone-confined metastatic
disease, lymph node only and bone þ lymph node and those
with visceral metastatic disease identified by brain, lung, liver and
cutaneous metastases.
Methylation analysis
We identified a CpG island in the 50 regulatory sequences of NT5E
(http://www.genome.ucsc.edu/cgi-bin/hgGateway) and tested pos-
sible association between aberrant methylation in the CpG island
and downregulation of mRNA expression using methylation-
specific PCR (MSP) and pyrosequencing. DNA (0.5 mg) was
modified by sodium bisulphite using the Zymo EZ DNA
Methylation kit (Zymo Research, Irvine, CA, USA). This process
converts unmethylated cytosine residues to uracil, whereas
methylated cytosine residues remain unchanged. Bisulphite-
modified DNA was used as a template for methylation-specific
PCR and pyrosequencing. CpGenome Universal Methylated DNA
(Zymo Research) and normal human unmethylated DNA were
used as positive and negative controls, respectively, in each
experiment. Primers for methylation-specific PCR:
M forward primer: 50-TATTTTATGAACGTTTTGCGTTACG-30
M reverse primer: 50-CTAAACTTACCACACTCTACCATCCG-30
U forward primer: 50-ATTTTATGAATGTTTTGTGTTATGA-30
U reverse primer: 50-AACTTACCACACTCTACCATCCACT-30
Each PCR was performed at least three times and scored
independently by two observers.
Primers for pyrosequencing amplified a 170-bp fragment from
the NT5E CpG island.
Sequences were as follows:
PCR F 50-GTATTAGGGTATTATTTGGTTTAT-30
PCR R 50- BIOT -CTTACCACACTCTACCATCC-30
Polymerase Chain Reaction conditions were: 95 1C for 10min,
95 1C for 30 s/54 1C for 30 s/72 1C for 40 s for 40 cycles, 72 1C for
7min. PCR products were resolved on 2% agarose gels, visualised
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using a transilluminator, then analysed by pyrosequencing
(Biotage Sample Prep kit, using forward primer). Analysis of %
methylation at each CpG dinucleotide was performed using CpG
Software (Qiagen). Placental DNA was used as negative control of
methylation (0% average methylation) and a commercial methy-
lated DNA (Millipore, Waltford, UK) was used as positive control
(98% average methylation). The RasL12 CpG island was analysed
using bisulphite sequencing and methylation-specific PCR.
Location of primers for methylation-specific PCR and bisulphite
sequencing is shown in Figure 7.
NT5E expression analysis
For qPCR analysis of expression, total RNA was isolated using the
RecoverAll Total Nucleic Acid Isolation (Ambion, Austin, TX,
USA). Twenty-five microlitre PCR reactions were performed using
50 ng of cDNA obtained by reverse transcription. Amplification
and analysis were done according to the manufacturer’s protocol
in 96-well plates in an ABI PRISM 7000 Sequence Detection System
(Applied Biosystems, Foster City, CA, USA) and the pre-cast
‘TaqMan Gene Expression Assays’ (Applera, https://products.ap-
pliedbiosystems.com/) for NT5E (Hs001573922_m1). Quantifica-
tion of the target transcript was performed in comparison to the
reference transcript b2microglobulin (Hs99999907_m1), using the
‘delta-delta Ct method’ for comparing relative expression results in
real-time PCR as outlined by PE Applied Biosystems (Perkin
Elmer, Foster City, CA, USA).
Statistics
CpG island methylation status and presence or metastatic
profile were assessed for associations using Fisher’s exact test.
Kaplan–Meier curves were used to estimate the probabilities of
overall survival (OS) and disease-free survival (DFS) and the
log-rank test to assess the statistical significance of differences in
event rates. All statistical analyses were performed using Prism 5
(GraphPad software, Inc., La Jolla, CA, USA). Overall survival was
defined as time from treatment start to death from any cause, or
last follow-up date. Disease-free survival was defined as time from
treatment start to disease progression or death for any cause.
Living patients without evidence of progression were censored at
the last follow-up. Analysis of the risk of death for the 157 tumours
from Tayside was conducted using Cox proportional-hazards
regression modelling. We examined the relationship between OS
and the methylation status of the NT5E CpG island and known
clinico-pathological parameters, including tumour size, tumour
grade, ER status, PgR status, nodal status and HER-2.
RESULTS
NT5E expression is regulated epigenetically in breast
cancer
Methylation in the NT5E CpG island was detectable in MDA MB
361, MDA MB 436, MDA MB 453, MCF-7, GI101, T47D, MCF12A
and ZR75.1 cell lines (Figure 1A). By methylation-specific PCR,
methylation was complete (no detecteable amplification in the
U-specific PCR) in MDA MB 453 and T47D and partial in the
remaining cell lines (amplification of both U- and M-specific PCR).
There was no detectable methylation in MDA MB157, MDA MB
231, MDA MB 468, NCI, BT20 and CAL51 (Figure 1A). To validate
and extend these results, we performed pyrosequencing analysis of
the NT5E CpG island in breast cancer cell lines. These included a
subset of those analysed by methylation-specific PCR, together
with additional lines not previously analysed (Figure 1B). Average
methylation in the CpG island was 94% in MDA MB 453 and 88%
in T47D, consistent with methylation-specific PCR (Figure 1B).
There was partial methylation in MDA MB 436 (35%) and MCF-7
(26%) again consistent with methylation-specific PCR. MDA
MB 231 and MDA MB 468 had average methylation levels of 2%,
also in agreement with methylation-specific PCR (summarised in
Table 1). Next, we assessed expression of NT5E mRNA using RT–
PCR and correlated this with methylation status. These data
(Figure 1, Table 1) imply a close correlation between methylation
in the NT5E CpG island and absent/downregulated expression of
NT5E mRNA. To further test this association, we used qPCR to
analyse mRNA levels, initially in normal breast cells and cell lines
with CpG island methylation. Expression was undetectable in MDA
MB 453 and T47D (lines with almost complete methylation of the
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Figure 1 Methylation-dependent transcriptional silencing of NT5E in
breast cancer cell lines. (A) Methylation in the NT5E CpG island correlates
with downregulation of mRNA expression. The figure shows MSP analysis
of the NT5E CpG island (upper panels) and semi-quantitative RT–PCR
analysis of NT5E mRNA and the control gene GAPDH in breast carcinoma
cell lines (bottom panels). MSP was performed as described in Materials
and Methods. The figure shows unmethylated (U) and methylated (M)
reactions for each cell line DNA. Also shown are control U and M
DNA samples modified in parallel with the cell line DNA samples.
(B) Pyrosequencing analysis of the NT5E CpG island in breast carcinoma
cell lines. Pyrosequencing was done as described in Materials and Methods.
The level of methylation is represented by the intensity of shading in the
circles, each of which represents an individual CpG dinucleotide in the
amplified fragment. The mean % CpG methylation in the amplified
fragment, together with the methylation-specific PCR analysis is also shown.
Abbreviation: ND¼ not determined.
Table 1 Methylation in the NT5E CpG island in breast carcinoma cell lines
Cell line Phenotype ER PgR HER-2
NT5E
(MSP)
NT5E (pyro-
sequencing %)
MDA MB 157 (Basal)   N U ND
MDA MB 231 (Basal)   N U 2
MDA MB 361 (Luminal) þ  Amp U/M ND
MDA MB 436 (Basal)   N U/M 35
MDA MB 453 (Luminal)   Amp M 94
MDA MB 468 (Basal)   N U 2
MCF-7 (Luminal) þ þ N U/M 26
MCF12A (Basal)   N U/M ND
GI101 (Basal þ  N U/M ND
T47D (Luminal) þ þ N M 88
BT20 (Basal)   N U ND
CAL51 (Basal)   N U ND
BT549 (Basal)   N ND 3
ZR75.1 (Luminal) þ  N U/M ND
HCC1937 (Basal)   N ND 2
SKBR3 (Luminal)   Amp ND 3
Abbreviations: Amp¼Amplified; ER¼ oestrogen receptor; M¼methylated;
MSP¼methylation-specific PCR; ND¼ not determined; PgR¼ progesterone
receptor; U¼Unmethylated. Data on cell line phenotypes, ER, PgR and Her-2 are
from Mackay et al (2009).
NT5E in breast cancer
C Lo Nigro et al
77
& 2012 Cancer Research UK British Journal of Cancer (2012) 107(1), 75 – 83
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
NT5E CpG island) and downregulated relative to normal breast
epithelium in MDA MB 436 and MCF-7 (partially methylated NT5E
CpG island) (Figure 2A). Having confirmed correlation between
methylation and downregulation of mRNA, we next analysed a
larger panel of cell lines again using qPCR. NT5E mRNA was
expressed at high levels in HCC1937 (BRCA1-associated TNBC),
MDA MB 231 (TNBC), BT549 (TNBC) and SKBR3 (ER ,
PgR and HER-2þ ) (Figure 2B). All cell lines that overexpressed
NT5E were unmethylated as determined by MSP and pyrosequen-
cing. To further test the association of mRNA silencing with
aberrant CpG methylation, we analysed the effect of the
demethylating agent azacytidine (50 AZA) in MCF-7 cells in which
the CpG island was partially methylated and expression down-
regulated. Twenty-four hours after exposure to 50 AZA there was
an increase in NT5E mRNA levels and this increased further to a
maximum three-fold upregulation after 96 h of 50-AZA exposure
(Figure 2C). Together, data from Figures 1 and 2 imply that the
NT5E CpG island is unmethylated and the gene expressed at high
levels predominantly but not exclusively in hormone receptor
negative breast cancer cell lines, whereas, conversely, methylation-
dependent silencing of NT5E occurs more commonly in hormone
receptor-positive cell lines.
NT5E CpG island methylation associates with non-visceral
predominant metastatic disease
The in vitro data prompted us to investigate methylation in the NT5E
CpG island in clinical cases of breast cancer. We first analysed using
pyrosequencing DNA extracted from 83 formalin-fixed, paraffin-
embedded primary breast cancer cases from Northern Italy (Figure 3).
These cases comprised 79 ER-positive cancers treated adjuvantly
with endocrine therapy and 4 ER-negative cases. The NT5E CpG
island was methylated in 40/79 (51%) ER-positive cases. We asked
whether methylation of the NT5E CpG island in primary
ER-positive cases was associated with loco-regional and/or distant
metastatic relapse. Representative pyrosequencing is shown in
Figure 3A. The NT5E CpG island was densely methylated in 16 of
21 (76%) patients who developed non-visceral metastatic disease
compared with 6/28 cases with visceral metastases (21%)
(P¼ 0.0002, OR¼ 11.73). Interestingly, the NT5E CpG island was
unmethylated in all four ER-negative cases and visceral metastatic
relapse occurred in 3/4 of these cases.
NT5E CpG island methylation in metastatic breast cancer
Data from primary cancers suggest that NT5E may influence the
anatomical site of relapse. To further address this observation, we
performed pyrosequencing analysis of 23 resected CNS metastases
(series II) from patients with primary breast carcinomas. In each
case, the diagnosis of metastatic breast cancer was confirmed
by histopathological analysis and receptor expression studies (ER,
PgR and HER-2). Of the 23 cases, 14 were ER negative and 8 of
these 14 cases were TNBC. 10/14 ER-negative cases were negative
for NT5E methylation and 6/8 TNBC were negative (Figure 4).
Methylation in the NT5E CpG island varies with
acquisition of a metastatic phenotype
Our data imply selective pressure for overexpression of NT5E in at
least a subset of cases of metastatic breast cancer, particularly in
ER negative and TNBC cases. However, it is clear that some
primary cancers, with high level of NT5E CpG island methylation,
nonetheless ultimately relapsed in visceral sites. This prompted us
to ask whether the methylation status of the NT5E CpG island
changes in metastatic lesions relative to primary lesions. Using
pyrosequencing, we analysed four cases in series II (all TNBC) for
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Figure 2 (A) Downregulation of NT5E mRNA correlates with CpG
methylation in ER-positive breast carcinoma cell lines. Expression of NT5E
mRNA was determined by qPCR and % methylation by pyrosequencing.
Downregulation correlates with methylation. (B) NT5E mRNA is over-
expressed in breast carcinoma cell lines lacking CpG island methylation.
Average % methylation in the NT5E CpG island was determined by
pyrosequencing and expression of NT5E mRNA by qPCR (relative to
normal breast epithelium). (C) Demethylation reactivates NT5E expres-
sion. MCF-7 cells were treated with AZA and harvested at the indicated
times (in hours). Total RNA was isolated and levels of NT5E mRNA
determined by qPCR as described in Materials and Methods.
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Figure 3 NT5E CpG island methylation is more common in cancers
relapsing in non-visceral metastatic sites in ER-positive breast cancer.
(A) Representative pyrosequencing analysis of the NT5E CpG island in
primary breast carcinomas. The predominant site of metastatic relapse is
indicated. Pyrosequencing analysis was performed as described in Materials
and Methods. The % methylation at each analysed CpG dinucleotide is
represented by the intensity of shading in the circles as shown in the figure,
together with the mean % methylation for each case. (B) Graph showing
proportion of methylation-positive cases in ER-positive primary breast
cancers, treated with endocrine therapy, which subsequently relapsed at
different metastatic sites. Primary carcinomas which relapsed with
metastasis to brain, liver, lung and skin are designated ‘visceral’. Bone and
lymph node metastasis are designated as ‘non-visceral’.
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which paired primary and CNS metastatic tissue was available to
us. There was no change in the status of ER, PgR or HER-2 between
the primary and metastatic lesions in each case (Figure 4).
Nevertheless in three cases of the CNS metastases there was a clear
loss of methylation in the NT5E CpG island relative to the paired
primary lesion, consistent with selection of cell clones lacking
methylation (Figure 4). In the 4th case, methylation levels were low
in the primary carcinoma and remained low in the CNS metastasis
(Figure 4).
NT5E CpG island methylation is an independent breast
cancer biomarker
The apparent association between the methylation status of the
NT5E CpG island and the site specificity of metastasis prompted us
to extend the investigation to an independent cohort of primary
breast cancers, for which complete and long-term follow-up data
were available. This series (series III) comprised 157 primary
cancers cases (119 ER positive and 38 ER negative, of which 26
were TNBC; Table 2). Fifty-two patients had developed metastatic
disease at the time of censoring. Methylation was detected in 96/
157 (61%) cases (Figure 5A), which is comparable to the first series
analysed (51%). Methylation was detected in both ER-positive
(77/119; 0.65) and ER-negative (19/38; 0.5) cases. Patients whose
primary tumours, were positive for NT5E CpG island methylation,
were less likely to develop metastasis than those lacking
methylation (P¼ 0.003, OR¼ 0.34, 95% CI: 0.17–0.69). When
analysing by histological subtype, we confirmed the association of
CpG island methylation with lower probability of metastasis in ER
negative (P¼ 0.049, OR¼ 0.21, 95% CI: 0.05–0.83) and in TNBC
cases (P¼ 0.017, OR¼ 0.09, 95% CI: 0.01–0.55) (Figure 5B), but in
the cohort of 119 ER-positive cases, this association just failed
to reach statistical significance (P¼ 0.08, OR¼ 0.4271, 95%
CI: 0.20–1.09) (Figure 5B). When all cases were analysed, NT5E
CpG island methylation was more common in those with
non-visceral compared with visceral metastatic disease (P¼ 0.01,
OR¼ 11.8). When analysing by histological subtype, this associa-
tion was significant in ER-negative cases (P¼ 0.02, OR¼ 22), but
did not reach significance in ER-positive cases (P¼ 0.33).
Consistent with this observation, in cases with visceral metastases,
the frequency of unmethylated NT5E CpG island was lower in ER-
positive cases than in ER-negative cases (12/49 vs 12/19; P¼ 0.02,
OR¼ 4.28). We then investigated NT5E CpG island methylation as
a determinant of disease outcome in the same series, using time-
dependent endpoints. Patients with tumours lacking detectable
NT5E CpG island methylation had increased probability of shorter
DFS (P¼ 0.001, HR 2.7, Figure 5C) and OS (P¼ 0.001, HR¼ 3,
Figure 5D). In subgroup analysis, unmethylated NT5E CpG island
was also associated with increased risk for poorer survival in ER
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dinucleotide in the amplified fragment. The mean % CpG methylation in
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Table 2 (A) Clinico-pathological characteristics of patients (n¼ 157);
(B) Multivariate analysis of prognostic factors
Characterstic
Number of cases
(frequency)
(A)
Grade 1 29 (0.19)
Grade 2 60 (0.39)
Grade 3 63 (0.41)
Missing 5
Stage 1 63 (0.41)
Stage 2 87 (0.56)
Stage 3 6 (0.03)
Missing 2
Node positive 69 (0.45)
Node negative 83 (0.55)
Missing 5
ER positive 119 (0.76)
ER negative 38 (0.24)
PgR positive 84 (0.54)
PgR negative 73 (0.46)
HER-2 positive 19 (0.12)
HER-2 negative 136 (0.88)
Missing 2
TP53 mutation 46 (0.29)
TP53 wild-type 111 (0.71)
NT5E methylated (ER positive) 77 (0.65)
NT5E methylated (ER negative) 19 (0.5)
(B)
Variable Hazard ratio P-value 95% CI
Tumour grade 1.548 0.002 1.168–2.052
Nodal status 1.099 0.000 1.043–1.160
ER positive 0.372 0.12 0.107–1.291
PgR positive 0.497 0.182 0.178–1.387
TP53 mutation 2.041 0.08 0.919–4.529
NT5E
methylation
0.328 0.010 0.141–0.765
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negative (P¼ 0.011, HR¼ 3.27, 95% CI: 1.31–8.12, Figure 6) and in
TNBC (P¼ 0.004, HR¼ 6.2, 95% CI: 1.9–20 Figure 6), but
not in patients with ER-positive tumours (P¼ 0.35, HR¼ 1.64,
95% CI: 0.57–4.68). To further confirm that the effects of NT5E
CpG island methylation are not the result of a non-specific
‘methylator’ phenotype, we tested the effects on clinical outcome of
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Figure 5 Methylation of the NT5E CpG island in primary breast carcinomas influences clinical outcome. (A) Representative methylation-specific PCR
analysis of the NT5E CpG island in series III breast carcinomas. The figure shows unmethylated (U) and methylated (M) reactions for each individual case
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analysed by MSP and statistical analysis done as described in Materials and Methods. The figure shows DFS in primary cancers either M or U.
(D) Kaplan–Meir analysis of OS in primary breast carcinomas according to methylation status of NT5E CpG island. Methylation in the NT5E CpG island was
analysed by methylation-specific PCR and statistical analysis done as described in Materials and Methods. The figure shows OS in primary cancers either
M or U. Abbreviations: ALL¼ entire patient population; ER ¼ oestrogen receptor negative; ERþ ¼ oestrogen receptor positive; MSP¼methylation-
specific PCR; TNBC¼ triple-negative breast cancer.
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a second novel epigenetically regulated gene, RasL12, in the same
patient population. We initially showed using bisulphite sequen-
cing and methylation-specific PCR that RasL12 is subject to CpG
island methylation in many breast carcinoma cell lines, with a
perfect correlation between bisulphite sequencing and methyla-
tion-specific PCR and downregulated expression of RasL12
(Figure 7A and Figure 7B). We then analysed the same patient
population using methylation-specific PCR (Figure 7C). There was
methylation in the RasL12 CpG island in 48/157 (31%) cases.
Methylation in the RasL12 CpG island did not significantly
affect median DFS or median OS. For DFS: P¼ 0.5339, HR¼
0.7939, 95% CI: 0.3836–1.643; for OS: P¼ 0.3854, HR¼ 0.7608, 95%
CI: 0.4104–1.410.
NT5E CpG island methylation status and outcome after
adjuvant chemotherapy
We then asked whether the methylation status of NT5E affects
clinical outcome in patients who received adjuvant chemotherapy.
Disease-free survival in patients who received chemotherapy was
significantly shorter in patients with unmethylated NT5E CpG
island (P¼ 0.0016, HR¼ 5.1, 95% CI: 1.8–14.37). Similarly, OS was
shorter in cases with unmethylated NT5E CpG island (P¼ 0.0005,
HR¼ 7.4, 95% CI: 2.416–23.08).
NT5E CpG island methylation is inversely correlated
with TP53 mutation
Finally, we performed multivariate analysis to assess the prog-
nostic significance of NT5E CpG island methylation in series III
(Table 2). This analysis revealed that NT5E methylation retained
significance after multivariate analysis of known prognostic
variables (HR¼ 0.328, 95% CI: 0.141–0.765; P¼ 0.010). Further,
we found that NT5E CpG island methylation was inversely
associated with TP53 mutation (Po0.005).
DISCUSSION
Here, we report that NT5E (CD73) expression is regulated in
breast cancer by the methylation status of the CpG island and that
methylation is a prognostic indicator of favourable clinical
outcome. Previous work has identified involvement of NT5E
expression in cancer behaviour (Zhi et al, 2010), but this is to the
best of our knowledge the first demonstration that NT5E is an
independent prognostic marker in human cancer.
We have shown using two techniques, methylation-specific PCR
and (quantitative) pyrosequencing, that downregulation of NT5E
mRNA correlates well with methylation in the CpG island in breast
cancer. In addition, we found that the NT5E CpG island is
unmethylated and mRNA expressed in normal breast epithelial
cells, while the hypomethylating compound 50 AZA restores
expression in breast cancer cell lines. Together, these observations
imply that aberrant CpG methylation is an important mechanism
of NT5E silencing in breast cancer and that silencing is specific for
neoplasia. The expression analysis we report in breast cancer cell
lines is consistent with previous work (Spychala et al, 2004;
Mackay et al, 2009). We confirm and extend these expression
analyses by showing that CpG island methylation is a key regulator
of NT5E expression and the predominant mechanism of down-
regulation in breast cancer cell lines. Our results also further
extend previous data by showing that expression in ER-positive
(predominantly luminal) breast carcinoma cell lines is down-
regulated by methylation-dependent transcriptional silencing and
that in the absence of methylation (most commonly, but not
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Figure 7 Methylation-dependent transcriptional silencing of RasL12 in breast cancer. (A) Bisulphite sequencing analysis of RasL12 CpG island. The figure
shows a map of the RasL12 CpG island with the position of primers indicated for bisulphite sequencing (Bis F and Bis R) and methylation-specific PCR
(MSP MF, MSP UF, MSP MR and MSP UR). Vertical lines below the scale represent individual CpG dinucleotides within the CpG island. The density of
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panel) in breast cancer cell lines. The figure shows U- and M-specific PCR reactions for each cell line and RT–PCR. (C) MSP analysis of RasL12 CpG island
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exclusively, seen in ER negative and triple-negative cell lines),
NT5E is often greatly overexpressed.
To assess the clinical significance of our cell line observations,
we extended the study to primary breast carcinomas. Given the
potential importance of NT5E as a mediator of malignant
progression and metastasis, studies of NT5E expression in clinical
cases of breast cancer have been remarkably limited. One such
study, performed 20 years ago, employed immunohistochemical
analysis of NT5E in an unselected series of breast carcinomas and
showed that expression was detected inB10% (Kruger et al, 1991).
More recently, it was shown in a small series of clinical cases
that NT5E was underexpressed predominantly in ER-positive
breast carcinomas and more commonly overexpressed in TNBC
(Spychala et al, 2004). Our data, in three independent series of
breast carcinomas, are clearly consistent with both previous
studies. Furthermore, we show in a series of ER-positive cases
treated with adjuvant endocrine therapy that bone predominant
disease, a clinical entity with a typically indolent clinical course
(Andrade et al, 2011), is more common in cases with dense
NT5E CpG island methylation, whereas visceral and CNS
metastases predominate in cases lacking dense NT5E methylation.
We confirmed these results in a second-independent clinical series
containing ER positive, ER negative and TNBC. Aggressive disease,
with visceral and/or brain metastases, is more likely in cases that
lack methylation in the NT5E CpG island, than in those with
methylation. Our data are consistent with the observation that
overexpression of NT5E in an experimental model of breast cancer
promotes metastasis to the lungs via activation of A2B adenosine
receptors (Stagg et al, 2011).
Despite this strong propensity for cases lacking methylation to
metastasise to viscera and brain, it is clear that (in a minority of
cases) clinically aggressive disease develops from primary breast
cancers in which the NT5E promoter CpG island is methylated.
We propose two potential explanations for this. First, knock-down
of NT5E causes increased cell migration in some cell types
(Andrade et al, 2011). It is therefore possible that, perhaps in early
disease, methylation-dependent silencing of NT5E might promote
enhanced migration in a subset of breast carcinomas through as
yet undefined mechanisms. Second, we have shown in the present
study that the methylation status of the NT5E CpG island often
changes from methylated to unmethylated in cases which have
metastasised to brain, when compared with the primary breast
carcinoma from which they derived, implying a strong selective
pressure favouring (re-) expression of NT5E in aggressive breast
cancers. The numbers of such paired cases available to us was
limited. However, to the best of our knowledge, this is the first
demonstration of dynamic epigenetic change in a specific gene
from primary carcinoma to brain metastasis in breast cancer.
Changes in expression of steroid hormone receptors and HER-2
between primary and recurrent disease are now well described
(Aitken et al, 2010; Thompson et al, 2010) and changes in the
epigenetic status of NT5E provide further evidence of a dynamic
transcriptional process underlying metastasis.
To validate methylation in NT5E as an independent prognostic
marker, we tested a second novel epigenetically regulated gene,
RasL12. We showed using bisulphite sequencing and methylation-
specific PCR that expression of RasL12 is silenced by methylation
in breast carcinoma cell lines and in primary breast carcinomas.
Understanding of the precise role of RasL12 in breast cancer awaits
additional studies. However, the absence of any predictive effect of
RasL12 on clinical outcomes in our series of cases strongly
endorses the specific biomarker candidacy of NT5E methylation.
In addition to influencing metastatic potential in breast cancer,
we demonstrate that the methylation status of NT5E also affects
outcome in cases treated with (predominantly anthracycline)
chemotherapy. These results are supported by previous work in
cell lines resistant to anthracyclines (Ujhazy et al, 1994; Mikhailov
et al, 2008). Depletion of NT5E mediated by inhibitory RNA causes
increased apoptosis and reduction in cell growth rate in MDA MB
231 cells consistent with the clinical importance of NT5E CpG
island methylation in TNBC and particularly with its strong
predictability of favourable outcome to adjuvant chemotherapy,
potentially by intervening in accumulation of intracellular
nucleotides that have been shown to act as critical pro-survival
factors (Chandra et al, 2006). A further potential mechanism
linking absence of methylation with less favourable outcome
after chemotherapy is the highly significant association
between absence of NT5E CpG island methylation and mutation
in TP53.
The recognised role of NT5E in promoting invasion and
metastasis (Wang et al, 2008) taken together with the frequent
absence of methylation in NT5E in ER negative and TNBC, which
we demonstrate in the present work, implies that inhibition of
NT5E may be an attractive therapeutic strategy in these subtypes of
breast cancer. Strategies to inhibit or block NT5E clearly merit
consideration in breast cancer particularly in the difficult to treat
TNBC and ER-negative cases. Conversely, our results may have
implications in the potential use of demethylating agents in breast
(and other) solid tumours. This approach has been considered
because the majority of genes affected by methylation-dependent
transcriptional silencing in cancer are tumour suppressor genes or
genes silenced by methylation in cancers with acquired chemo-
therapy resistance. Re-expression of such genes would have likely
therapeutic value. Our data imply that reactivation of NT5E would
have deleterious effects by promoting a more aggressive phenotype
and potentially resistance to chemotherapy. Identification of
patients likely to benefit from use of demethylating agents might
be informed, at least in part, by profiling of the methylation status
of key genes, such as NT5E.
In conclusion, we show for the first time that NT5E is regulated
epigenetically in breast cancer, the epigenetic status of this
gene influencing metastasis and clinical outcome. We suggest
that NT5E promoter CpG island methylation may serve as a
promising favourable breast cancer epigenetic biomarker. NT5E is
expressed in normal breast tissue (http://www.proteinatlas.org/
ENSG00000135318). As such, the sensitivity of methylation
analysis and its specificity for neoplasia together suggest that
NT5E methylation analysis may be more informative and clinically
useful than immunohistochemistry or qPCR as a prognostic
biomarker. Our results warrant independent confirmation by other
groups before considering its investigation as a metastasis
predictor in clinical trials of adjuvant breast cancer therapies.
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